ALSO NOTED: Cephalon touts Fentora data; Northfield pursuing PolyHeme approval; FDA accepts NDA; and much more...

> Cephalon is reporting positive results from a study on its pain drug Fentora in non-cancer related pain. Fentora was approved last year for cancer pain. Release

> Even though its blood substitute PolyHeme has been linked to a higher death rate, Northfield Laboratories says it plans to pursue an FDA approval next year in cases where donor blood is not available. Release | Report

> The FDA accepted Summers Laboratories' new drug application for a head lice treatment that's been licensed by Sciele Pharma. The product kills lice through asphyxiation rather than with toxins. Release

> AdventRx Pharmaceuticals says that the FDA has provided fast track status for ANX-510, which is currently being investigated in a Phase III study, with 5-fluorouracil (5-FU) and bevacizumab for the initial treatment of metastatic colorectal cancer. Release

> Methodist Hospital in Houston has launched a bioinformatics project. FierceBioResearcher

> A new study has found that DTC ad spending on the rise. FiercePharma

> Rumor Mill: Novartis may make a bid for Bayer. FiercePharma

And Finally... The experts say that global warming is triggering an increase in flesh-eating diseases and pushing the development of new therapies. Report

Suggested Articles

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.